Laidlaw initiated coverage on shares of VBI Vaccines Inc. (NASDAQ:VBIV) in a research note issued to investors on Monday morning. The firm issued a buy rating and a $6.00 price target on the biopharmaceutical company’s stock.

Separately, Ladenburg Thalmann started coverage on shares of VBI Vaccines in a research report on Tuesday, July 26th. They issued a buy rating for the company.

VBI Vaccines (NASDAQ:VBIV) traded down 1.9277% during midday trading on Monday, reaching $3.1187. 4,813 shares of the company’s stock traded hands. VBI Vaccines has a 1-year low of $3.07 and a 1-year high of $4.40. The stock’s 50 day moving average price is $3.69 and its 200 day moving average price is $3.82. The firm’s market cap is $112.69 million.

An institutional investor recently raised its position in VBI Vaccines stock. BlackRock Fund Advisors raised its position in VBI Vaccines Inc. (NASDAQ:VBIV) by 1,701.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,789 shares of the biopharmaceutical company’s stock after buying an additional 42,303 shares during the period. BlackRock Fund Advisors owned about 0.14% of VBI Vaccines worth $177,000 as of its most recent filing with the SEC. 12.26% of the stock is owned by institutional investors.

VBI Vaccines Company Profile

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

5 Day Chart for NASDAQ:VBIV

Receive News & Stock Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related stocks with our FREE daily email newsletter.